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Abstract
Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may
develop either chronic HBV infection or, rarely, fulminant hepatitis.
Therefore there are elderly patients with severe acute HBV hepatitis caractherized by high serum
bilirubin levels >15 mmole/dl, international normalized ratio (INR) with value more than 1.6; these
patients are caractherized by a severe outcome of HBV infection.
As known, outcome of infection and the pathogenesis of liver diseases are determined by viral and
host factors, such as T reg lymphocytes.
T regs may be associated with a negative immune response such as an inhibition of gamma- IFN
secretion.
The impact of viral load on antiviral T cell responses may play a critical role in thaese patients,
influencing disease persistence and immune response.
Antiviral drugs could be useful in these patients determing a possible down -regulation of T regs.
Letter to the editor
Dear Editor,
Acute viral hepatitis B is cleared in more than 95% of
patients, while the remainder ones may develop either
chronic HBV infection or, rarely, fulminant hepatitis. [1] The
role of antivirals, such as lamivudine or entecavir, in acute
HBV infection, has not been evaluated in controlled trials.
Lamivudine administration shows an antiviral efficacy in
patients with HbeAg positive and HbeAg negative.
Among the patients with acute infection there are elderly
subjects with severe course and severe outcome of HBV
hepatitis.
A logical hypothesis for these patients is that a rapid
decrease in the HBVDNA levels trough the use of antiviral
agents could result in a less intense host response against
HBV virus.
Today, increased knowledge of the virological and immu-
nological events to HBV infection permits to define the
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mechanisms involved in viral clearance, persistence and
disease severity.
Outcome of infection and the pathogenesis of liver dis-
ease are determined by viral and host factors. [1]
The impact of viral load on antiviral T-cell responses has
been precisely characterized in animal models of viral
infections: a sustained presence of viral antigens leads to
virus specific T cell deletion [2].
In HBV infection the frequency and function of circula-
tory and intrahepatic HBV specific CD8 T cells is inversely
proportional to the level of HBV-DNA. [3]
The immunological defects could be proportional to the
level of HBV infection and inhibition of viral replication
and through antiviral treatment it is possible to obtaine a
partial restoration of HBV specific T cell immunity [4,5]
which is inadeguate in elderly patients. [6]
Moreover recent studies have provided evidence that a
population of specialized T cells are able to regulate the
immune response.
These cells reside mainly within a minor population of
CD4 cells that express the phenotype marker CD 25. [7]
They have been shown to suppress immunological
responses against self and foreign antigens through sup-
pressive cytokines.
It is possible that CD4+ CD25+ T cells are responsible for
the weak HBV specific T cell response in HBV infection
and may inhibit the expansion and function of HBV spe-
cific CD8 T cells precluding HBV clearance.
Some authors showed that the frequency of CD4+ CD25+
T cells positively correlate with HBVDNA load. [6]
This result suggests that an increased level of T regs may be
associated with a negative immune response, leading to
poor viral clearance.
Our hypothesis is that a decrease of HBV DNA load, deter-
mined by lamivudine treatment, determines a downregu-
lation of T regs.
T regs could be able suppressing the population and
gamma IFN production, mediated by HbsAg.
In summary, our findings suggest that it could be possible
a marked increase in circulating Tregs in elderly patients
with HBV infection.
Taken together these data, it is possible that antiviral drugs
might be useful in a selected group of old patients in
which HBV may cause a severe form of acute hepatitis,
caused by a decline of immunity and by the frequent pres-
ence of other morbidities.
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